233 related articles for article (PubMed ID: 25595253)
1. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
[TBL] [Abstract][Full Text] [Related]
2. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
3. Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP.
Klehmet J; Staudt M; Ulm L; Unterwalder N; Meisel A; Meisel C
J Neuroimmunol; 2015 Jun; 283():17-22. PubMed ID: 26004151
[TBL] [Abstract][Full Text] [Related]
4. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Gallia F; Balducci C; Nobile-Orazio E
J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
Dalakas MC
J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
[TBL] [Abstract][Full Text] [Related]
7. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Ritter C; Förster D; Albrecht P; Hartung HP; Kieseier BC; Lehmann HC
J Neuroimmunol; 2014 Sep; 274(1-2):225-9. PubMed ID: 25002077
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic immune-mediated neuropathies: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and the Lewis-Sumner syndrome.
Sederholm BH
Semin Neurol; 2010 Sep; 30(4):443-56. PubMed ID: 20941678
[TBL] [Abstract][Full Text] [Related]
10. The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy.
Bohn AB; Nederby L; Harbo T; Skovbo A; Vorup-Jensen T; Krog J; Jakobsen J; Hokland ME
Eur J Neurol; 2011 Jun; 18(6):919-24. PubMed ID: 21219545
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
Racosta JM; Sposato LA; Kimpinski K
Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
[TBL] [Abstract][Full Text] [Related]
12. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Lin CS; Krishnan AV; Park SB; Kiernan MC
Arch Neurol; 2011 Jul; 68(7):862-9. PubMed ID: 21747028
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.
Lucke IM; Adrichem ME; Wieske L; van der Kooi AJ; Verhamme C; van Schaik IN; Eftimov F
J Neurol Sci; 2019 Feb; 397():141-145. PubMed ID: 30623818
[TBL] [Abstract][Full Text] [Related]
14. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
15. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
16. Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins.
Trebst C; Brunhorn K; Lindner M; Windhagen A; Stangel M
Eur J Neurol; 2006 Dec; 13(12):1359-63. PubMed ID: 17116220
[TBL] [Abstract][Full Text] [Related]
17. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP.
Iijima M; Tomita M; Morozumi S; Kawagashira Y; Nakamura T; Koike H; Katsuno M; Hattori N; Tanaka F; Yamamoto M; Sobue G
Neurology; 2009 Oct; 73(17):1348-52. PubMed ID: 19776380
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?
Bick S; Tschernatsch M; Karg A; Fuehlhuber V; Trenczek TE; Faltermeier K; Hackstein H; Kaps M; Blaes F
J Neuroimmunol; 2013 Mar; 256(1-2):84-90. PubMed ID: 23357714
[TBL] [Abstract][Full Text] [Related]
19. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
Hughes RA
Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
[TBL] [Abstract][Full Text] [Related]
20. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Brannagan TH
Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
